» Articles » PMID: 39501053

Completely Non-invasive Prediction of IDH Mutation Status Based on Preoperative Native CT Images

Overview
Journal Sci Rep
Specialty Science
Date 2024 Nov 5
PMID 39501053
Authors
Affiliations
Soon will be listed here.
Abstract

The isocitrate dehydrogenase (IDH) mutation status is one of the most important markers according to the 2021 WHO classification of CNS tumors. Preoperatively, this information is usually obtained based on invasive biopsies, contrast-enhanced MR images or PET images generated using radioactive tracers. However, the completely non-invasive determination of IDH mutation status using routinely acquired preoperative native CT images has hardly been investigated to date. In our study, we show that radiomics-based machine learning allows to determine IDH mutation status based on preoperative native CT images both with very high accuracy and completely non-invasively. Based on independent test data, we are able to correctly identify 91.1% of cases with an IDH mutation. Our final model, containing only six features, exhibits a high area under the curve of 0.847 and an excellent area under the precision-recall curve of 0.945. In the future, such models may be used for a completely non-invasive prediction of important genetic markers, potentially allowing treating physicians to reduce the number of biopsies and speed up further treatment planning.

References
1.
Ohgaki H, Kleihues P . Epidemiology and etiology of gliomas. Acta Neuropathol. 2005; 109(1):93-108. DOI: 10.1007/s00401-005-0991-y. View

2.
Zeng T, Cui D, Gao L . Glioma: an overview of current classifications, characteristics, molecular biology and target therapies. Front Biosci (Landmark Ed). 2015; 20(7):1104-15. DOI: 10.2741/4362. View

3.
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn J, Minniti G . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170-186. PMC: 7904519. DOI: 10.1038/s41571-020-00447-z. View

4.
Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

5.
Wen P, Packer R . The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro Oncol. 2021; 23(8):1215-1217. PMC: 8328017. DOI: 10.1093/neuonc/noab120. View